• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Periodic Risk Evaluation Reports for Medical Device Adverse Events – New Guidelines Issued

Periodic Risk Evaluation Reports for Medical Device Adverse Events – New Guidelines Issued

Tuesday, 12 May 2020 / Published in Medical Device

Periodic Risk Evaluation Reports for Medical Device Adverse Events – New Guidelines Issued

On 06.05.2020, the NMPA (National Medical Products Administration) provided important details on the ongoing reporting requirements for NMPA-registered medical devices (including IVDs). The NMPA’s medical device supervision department, the National Center for Adverse Drug Reaction (ADR) Monitoring, has explained the timescale and data collection scope for preparing and submitting the initial periodic evaluation report for medical devices according to the Administrative Measures on the Monitoring and Re-evaluation of Medical Device Adverse Events (Order No. 1 of the General Administration of Market Supervision and Administration) (abbr. as “the Measures”):

  1. Class II and Class III medical device registrants should submit periodic risk evaluation reports for 2020 following the requirements of the Measures. If the due date is earlier than 30/09/2020, the registrants should submit the report before 30/09/2020.
  2. For class II and class III medical devices that are in the first registration cycle on 01/01/2019, the registrant should also submit the 2019 annual risk evaluation report before 30/09/2020.
  3. For medical devices in their first registration cycle, the registrant should submit a periodic risk evaluation report annually. The data collection start date should be consistent with the date on the registration certificate.
  4. Class I medical device registrants should submit a periodic risk evaluation report annually in the first five years after obtaining the filing certificate. But there is no need to write the reports afterward.
  5. For medical devices whose specifications were registered in different certificates (e.g. different specifications of disposable sterile syringes) or medical devices that must be used together with other devices under a different registration certificate (e.g. hip systems which include acetabular cups, femoral stems, etc.) can incorporate the risk assessments in one report and submit it before the earliest deadline. The registrant should indicate the information of related medical devices upon report submission or archiving. For medical devices of the same kind, the registrant intended to incorporate the risk assessments in one report, they should conduct a subgroup analysis based on the registration certificate number.

The English version is for reference only. In case of any discrepancy or ambiguity of meaning between this English translation and the Chinese version, the latter shall prevail.

This new reporting requirement is consistent with the NMPA’s push for continuous post-market surveillance. Since 2018, post market compliance, adverse event and annual reporting regulations are increasingly strict. It is important for companies with registered devices to be vigilant with their ongoing requirements and not take a “set-and-forget” approach. The role of NMPA Legal Agent is therefore increasingly important.

Cisema has 11 offices worldwide, five of which are in China. We can represent manufacturers as their NMPA Legal Agent for the complete product life cycle without their need to create a local entity in China. Contact us to talk through your particular requirements.

Read the Chinese version here.

By Jacky Li. Contact Cisema to learn more.

Tagged under: Periodic Risk Assessment Report

What you can read next

Biocompatibility Testing in China of Medical Devices: Regulatory Update
Public Consultation on Medical Device Standards
Hainan Communication SOP
Hainan Communication SOP for Medical Device Clinical RWD Applications (Trial)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.